ADMA Q4 2019 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+196.7% YoY

Gross Profit

$345,4462.9% margin

Operating Income

-$8M-65.0% margin

Net Income

-$11M-87.7% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+66.7%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$636,108

Balance Sheet

Total Assets

$127M

Total Liabilities

$101M

Stockholders' Equity

$26M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$4M	+196.7%
Gross Profit	$345,446	-$7M	+104.9%
Operating Income	-$8M	-$17M	+52.7%
Net Income	-$11M	-$18M	+41.5%

Revenue Segments

ADMA BioManufacturing

$11M91%

Plasma Collection Centers

$1M9%

Corporate

$35,7090%